Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable ...

In a touching tale of humanitarianism, Selva, an 11-year-old boy from Tiruchirappalli who survived Fanconi Anemia, met the ...

Canaccord Genuity analyst Whitney Ijem maintained a Buy rating on Rocket Pharmaceuticals (RCKT – Research Report) yesterday and set a ...

New Delhi: The Central government is set to launch a scheme to develop 12 indigenous drugs for eight rare diseases, health ...

The third and final risk to consider would be in terms of the regulatory filings and reviews of gene therapy RP-L102 for the treatment of patients with Fanconi Anemia [FA]. The risk here is that ...

Rocket Pharmaceuticals, Inc. RCKT announced that it has completed patient enrollment in a pivotal phase II study evaluating ...

Rocket’s lentiviral vector-based hematology portfolio consists of late-stage programs for Fanconi Anemia (FA), a difficult-to-treat genetic disease that leads to bone marrow failure and ...

CRANBURY, N.J., September 17, 2024--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic ...

After additional testing, it was discovered that she has a rare blood disorder, ‘Fanconi Anemia’ which has led to bone marrow failure. Now, Dylan and her father are admitted to St.

The community unites to host a music festival to fundraise for Dylan René, 6, and her father, Josiah Menard who are facing ...

RP-L102, Rocket's gene therapy in treatment of Fanconi Anemia, will likely have a BLA filing in Q4, 2024. In Pioneer, I pointed to the potential baked into its late-stage pipeline, while warning ...